| 1,054 | 0 | 113 |
| 下载次数 | 被引频次 | 阅读次数 |
人工智能是利用计算机、软件及算法等工具，模拟、延伸和增强人类智能的相关技术和系统。近年来，随着人工智能研究的不断深入及相关政策的推动，人工智能已在医疗卫生等多个领域取得了显著进展。与传统分析方法比较，人工智能的效率和性能更高。在此背景下，人工智能为临床药学的发展带来了新的机遇。目前，人工智能已逐步融入到传统药学服务中，包括药物重整、药物治疗方案的制订、处方前置审核、药物相互作用的预测、药物基因组学研究、药物相关基因检测及治疗药物监测和药品不良反应监测等，从而促进合理用药，减少不良反应的发生，提升药学服务的质量和效率。通过对人工智能在临床药学实践中的研究进展进行综述，进一步促进二者的融合，为未来制订更加精准、安全和有效的个体化药物治疗方案奠定基础。
Abstract：Artificial intelligence refers to technologies and systems that utilize computers, software, and algorithms to simulate, extend, and enhance human intelligence. In recent years, with the continuous advancement of research and the promotion of relevant policies, artificial intelligence has achieved significant progress in various fields, such as healthcare. Compared with traditional clinical data analysis, artificial intelligence demonstrates higher efficiency and superior performance. In this setting, artificial intelligence has introduced new opportunities for the development of clinical pharmacy, and their deep integration has become an inevitable trend. Currently, artificial intelligence is being progressively incorporated into traditional pharmaceutical services, enabling more efficient and accurate participation in multiple clinical tasks, such as medication reconciliation, pharmacotherapy regimen design, pre-prescription review, prediction of drug-drug interactions, pharmacogenomic studies, application of artificial intelligence in drug gene testing, therapeutic drug monitoring, and adverse drug reaction monitoring. These advancements facilitate rational medication use, reduce the incidence of adverse reactions, enhance the quality and efficiency of pharmaceutical services, and propel the evolution of clinical pharmacy as a discipline. This review summarizes relevant research on the application of artificial intelligence in clinical pharmacy, further promoting their integration and laying the foundation for developing more precise, safe, and effective individualized pharmacotherapy regimens in the future.
[1] GUPTA R, SRIVASTAVA D, SAHU M, et al. Artificial intelligence to deep learning:machine intelligence approach for drug discovery[J]. Mol Divers, 2021, 25(3):1315.
[2] RAMEZANI M, TAKIAN A, BAKHTIARI A, et al. The application of artificial intelligence in health policy:a scoping review[J].BMC Health Serv Res, 2023, 23(1):1416.
[3]杨艳平,李荣.基于机器学习的高维数据分类特征选择[J].湖南文理学院学报(自然科学版), 2025, 37(1):23.
[4]钱金栋,孙建国.深度学习在肿瘤智能放疗中的发展与展望[J].中国医疗设备, 2025, 40(1):149.
[5] YE L, ZHANG Y, YANG X Y, et al. An ovarian cancer susceptible gene prediction method based on deep learning methods[J].Front Cell Dev Biol, 2021, 9:730475.
[6] VASWANI A, SHAZEER N M, PARMAR N, et al. Attention is All you Need; proceedings of the Neural Information Processing Systems, F, 2017[C].
[7] THIRUNAVUKARASU A J, TING D S J, ELANGOVAN K, et al.Large language models in medicine[J]. Nat Med, 2023, 29(8):1930.
[8] MENG X B, YAN X Y, ZHANG K, et al. The application of large language models in medicine:a scoping review[J]. iScience,2024, 27(5):109713.
[9]冯光富,温慧敏,李儒杰,等.人工智能对医院药学的影响分析[J].中国药房, 2018, 29(16):2167.
[10] BEAVERS J, SCHELL R F, VANCLEAVE H, et al. Evaluation of inpatient medication guidance from an artificial intelligence chatbot[J]. Am J Health Syst Pharm, 2023, 80(24):1822.
[11] AYERS J W, POLIAK A, DREDZE M, et al. Comparing physician and artificial intelligence chatbot responses to patient questions posted to a public social media forum[J]. JAMA Intern Med,2023, 183(6):589.
[12] KRALJEVIC Z, BEAN D, SHEK A, et al. Foresight-a generative pretrained transformer for modelling of patient timelines using electronic health records:a retrospective modelling study[J].Lancet Digit Health, 2024, 6(4):e281.
[13] SHAO Y J, CHENG Y, NELSON S J, et al. Hybrid value-aware transformer architecture for joint learning from longitudinal and non-longitudinal clinical data[J]. J Pers Med, 2023, 13(7):1070.
[14] FALCONER N, ABDEL-HAFEZ A, SCOTT I A, et al. Systematic review of machine learning models for personalised dosing of heparin[J]. Br J Clin Pharmacol, 2021, 87(11):4124.
[15] LONG J, YUAN M J, POONAWALA R. An observational study to evaluate the usability and intent to adopt an artificial intelligencepowered medication reconciliation tool[J]. Interact J Med Res,2016, 5(2):e14.
[16] ZENG Q H, KLEIN C, CARUSO S, et al. Artificial intelligencebased pathology as a biomarker of sensitivity to atezolizumabbevacizumab in patients with hepatocellular carcinoma:a multicentre retrospective study[J]. Lancet Oncol, 2023, 24(12):1411.
[17] LIU J B, ZHANG Y M, CHEN N N, et al. Remote pharmacy service in primary care:the implementation of a cloud-based preprescription review system[J]. J Am Pharm Assoc(2003), 2021,61(2):e176.
[18] AKBULUT M, URUN Y. Onco-cardiology:drug-drug interactions of antineoplastic and cardiovascular drugs[J]. Crit Rev Oncol Hematol, 2020, 145:102822.
[19] ROMM E L, TSIGELNY I F. Artificial intelligence in drug treatment[J]. Annu Rev Pharmacol Toxicol, 2020, 60:353.
[20] TRAN K A, KONDRASHOVA O, BRADLEY A, et al. Deep learning in cancer diagnosis, prognosis and treatment selection[J].Genome Med, 2021, 13(1):152.
[21] IORIO F, KNIJNENBURG T A, VIS D J, et al. A landscape of pharmacogenomic interactions in cancer[J]. Cell, 2016, 166(3):740.
[22] RODRIGUEZ S, HUG C, TODOROV P, et al. Machine learning identifies candidates for drug repurposing in Alzheimer's disease[J]. Nat Commun, 2021, 12(1):1033.
[23] CHEN X, SHEN F, GONZALUDO N, et al. Cyrius:accurate CYP2D6 genotyping using whole-genome sequencing data[J].Pharmacogenomics J, 2021, 21(2):251.
[24]陈晶.个体化药物基因检测开启“精准用药新时代”[N].人民政协报, 2024-12-04(10).
[25] LI D Y, PAIN O, FABBRI C, et al. Metabolic activity of CYP2C19a n d C Y P 2 D 6 o n a n t i d e p r e s s a n t r e s p o n s e f r o m 1 3 c l i n i c a l studies using genotype imputation:a meta-analysis[J]. Transl Psychiatry, 2024, 14(1):296.
[26] WESTERGAARD N, LUND T M, VERMEHREN C. Predictive biomarkers and personalized therapy:use of pharmacogenetic testing in a Scandinavian perspective[J]. Basic Clin Pharmacol Toxicol, 2025, 136(3):e70009.
[27] SERRANO D R, LUCIANO F C, ANAYA B J, et al. Artificial intelligence(AI)applications in drug discovery and drug delivery:revolutionizing personalized medicine[J]. Pharmaceutics, 2024,16(10):1328.
[28]詹世鹏,马攀,刘芳.机器学习在治疗药物监测与个体化用药中的应用[J].中国药房, 2023, 34(1):117.
[29] DEIGIN V I, VINOGRADOVA J E, VINOGRADOV D L, et al.Thymodepressin-unforeseen immunosuppressor[J]. Molecules,2021, 26(21):6550.
[30] LI T F, HU L, MA X L, et al. Population pharmacokinetics of cyclosporine in Chinese children receiving hematopoietic stem cell transplantation[J]. Acta Pharmacol Sin, 2019, 40(12):1603.
[31] CANDELA-BOIX M R, RAMóN-LóPEZ A, NALDA-MOLINA R, et al. Population pharmacokinetics models of sirolimus in renal transplant patients:a systematic review[J]. Farm Hosp, 2021,45(7):77.
[32]傅晓华,洪晓丹,刘石带,等.人工神经网络模型在肾移植患者他克莫司个体化给药中的应用[J].中国药学杂志, 2013, 48(12):1000.
[33] NODA T, MIZUNO S, MOGUSHI K, et al. Development of a predictive model for nephrotoxicity during tacrolimus treatment using machine learning methods[J]. Br J Clin Pharmacol, 2024,90(3):675.
[34] MO X L, CHEN X J, IEONG C, et al. Early prediction of tacrolimus-induced tubular toxicity in pediatric refractory nephrotic syndrome using machine learning[J]. Front Pharmacol, 2021,12:638724.
[35] ZHENG P, YU Z, LI L R, et al. Predicting blood concentration of tacrolimus in patients with autoimmune diseases using machine learning techniques based on real-world evidence[J]. Front Pharmacol, 2021, 12:727245.
[36] BEYDOUN A, DUPONT S, ZHOU D, et al. Current role of carbamazepine and oxcarbazepine in the management of epilepsy[J]. Seizure, 2020, 83:251.
[37]张颖,孙玉鹤,周甜甜,等.六种抗癫痫药物的血药浓度监测结果分析[J].临床心身疾病杂志, 2024, 30(4):120.
[38]张蕾,徐毅超,陈金亮,等.应用人工神经网络法预测癫痫患者血浆中拉莫三嗪浓度[J].中国医院药学杂志, 2020, 40(8):909.
[39]杨泽萍,马雪,李红健,等. GA-BP神经网络、多元线性回归预测新疆癫痫患儿拉莫三嗪血药浓度[J].中国药师, 2022, 25(9):1598.
[40]赵婷,李红健,章立华,等.基于人工神经网络模型的新疆维吾尔族癫痫患儿左乙拉西坦血清药物浓度预测研究[J].中国现代应用药学, 2021, 38(22):2875.
[41] MONTANéE, SANTESMASES J. Adverse drug reactions[J].Med Clínica Engl Ed, 2020, 154(5):178.
[42] AHMAD A, PATEL I, BALKRISHNAN R, et al. An evaluation of knowledge, attitude and practice of Indian pharmacists towards adverse drug reaction reporting:a pilot study[J]. Perspect Clin Res, 2013, 4(4):204.
[43] SALAS M, PETRACEK J, YALAMANCHILI P, et al. The use of artificial intelligence in pharmacovigilance:a systematic review of the literature[J]. Pharmaceut Med, 2022, 36(5):295.
[44] HU Q Z, WU B, WU J H, et al. Predicting adverse drug events in older inpatients:a machine learning study[J]. Int J Clin Pharm,2022, 44(6):1304.
[45] MINERALI E, FOIL D H, ZORN K M, et al. Comparing machine learning algorithms for predicting drug-induced liver injury(DILI)[J]. Mol Pharm, 2020, 17(7):2628.
[46]张颖,于泽,许本善,等.人工智能指导个体化用药的研究与实践[J].中国临床药学杂志, 2022, 31(2):151.
[47] KHAN B, FATIMA H, QURESHI A, et al. Drawbacks of artificial intelligence and their potential solutions in the healthcare sector[J].Biomed Mater Devices, 2023:1.
[48]周罗晶,邵旸,张瑞,等.智慧医疗场景下人工智能应用伦理问题与治理路径探讨[J].中国医院, 2024, 28(2):38.
[49] LI Y H, LI Y L, WEI M Y, et al. Innovation and challenges of artificial intelligence technology in personalized healthcare[J].Sci Rep, 2024, 14(1):18994.
[50] SARRAJU A, BRUEMMER D, VAN ITERSON E, et al.Appropriateness of cardiovascular disease prevention recommendations obtained from a popular online chat-based artificial intelligence model[J]. JAMA, 2023, 329(10):842.
基本信息:
DOI：10.19577/j.1007-4406.2025.09.004
中图分类号:R9;TP18
引用信息:
[1]佟欣,樊盼盼,宋晓轩,等.人工智能在临床药学实践中的研究进展[J].中国临床药学杂志,2025,34(09):663-668.DOI:10.19577/j.1007-4406.2025.09.004.